Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Bartlomiej M Getta, MBBS, Arnab Ghosh, MD PhD, Catherine C. Coombs, MD, Sean Devlin, PhD, Maria Arcila, MD, Abhinita Mohanty, Ross L. Levine, MD, Martin S. Tallman, MD, Ann A. Jakubowski, MD PhD, Sergio A. Giralt, MD, Alan M Hanash, MD PhD

Blood (2016) 128 (22): 3481.

https://doi.org/10.1182/blood.V128.22.3481.3481

Published: 2016

Journal Articles

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Melody Smith, MD, Arnab Ghosh, MD PhD, Scott James, MD PhD, Marco L Davila, MDPhD, Enrico Velardi, PhD, Kimon V. Argyropoulos, MD, Gertrude Gunset, Andrea Schietinger, PhD, Michel W. Sadelain, MD PhD, Marcel van den Brink, MD PhD

Blood (2016) 128 (22): 653.

https://doi.org/10.1182/blood.V128.22.653.653

Published: 2016

Journal Articles

Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof

Arnab Ghosh, MD PhD, Nicole Carreau, MD, Alessandra Moscatello, Adeeb Rahman, PhD, Jingjing Qi, Seunghee Kim-Schulze, PhD, Shyamala C. Navada, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2015) 126 (23): 4195.

https://doi.org/10.1182/blood.V126.23.4195.4195

Published: 2015

Journal Articles

CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd

Arnab Ghosh, MD, PhD, Marco L. Davila, MD, PhD, Lauren F. Young, BS, Christopher Kloss, BS, Gertrude Gunset, BS, Odette M. Smith, BA, Mallory L. West, BS, Natalie V. Singer, BS, Amanda M. Holland, BS, Robert R. Jenq, MD, Alan M. Hanash, MD, PhD, Jarrod A. Dudakov, PhD, Enrico Velardi, PhD, Yusuke Shono, MD, PhD, Michel Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2012) 120 (21): 451.

https://doi.org/10.1182/blood.V120.21.451.451

Published: 2012

Journal Articles

Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC

Arnab Ghosh, MD, PhD, Yildirim Dogan, PhD, Amanda M. Holland, BS, Odette M Smith, BA, Lauren F. Young, BS, Mallory L West, BS, Natalie V Singer, BS, Robert R Jenq, MD, Il-Kang Na, MD/PhD, Olaf Penack, MD/PhD, Alan M Hanash, MD, PhD, Martin G. Sauer, MD, Michel Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2011) 118 (21): 817.

https://doi.org/10.1182/blood.V118.21.817.817

Published: 2011

Journal Articles

Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd

Arnab Ghosh, MD, PhD, Amanda M. Holland, BS, Yildirim Dogan, PhD, Nury Yim, BS, Uttam K. Rao, BA, Lauren F. Young, BS, Odette M. Smith, BA, Robert Jenq, MD, Il-Kang Na, MD/PhD, Jennifer Tsai, MD, Olaf Penack, MD/PhD, Alan M. Hanash, MD, PhD, Martin G. Sauer, MD, Derek Sant'Angelo, PhD, Michel Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2010) 116 (21): 730.

https://doi.org/10.1182/blood.V116.21.730.730

Published: 2010

Journal Articles

TRAIL/ DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation.

Blood (2009) 114 (22): 234.

https://doi.org/10.1182/blood.V114.22.234.234

Published: 2009

Journal Articles

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

Il-Kang Na, MD, John Markley, MD, PhD, Jennifer Tsai, MD, Nury L. Yim, Bradley J. Beattie, Alexander D. Klose, PhD, Amanda M. Holland, Arnab Ghosh, MD, PhD, Uttam K. Rao, Matthias Stephan, MD, PhD, Inna Serganova, PhD, Renier J. Brentjens, MD, PhD, Ron R.G. Blasberg, MD, Michel W Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2009) 114 (22): 914.

https://doi.org/10.1182/blood.V114.22.914.914

Published: 2009

Journal Articles

The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease

Blood (2008) 112 (11): 65.

https://doi.org/10.1182/blood.V112.11.65.65

Published: 2008

NARROW

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof

CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd

Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC

Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd

TRAIL/ DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation.

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only